Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold
- 31 January 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (3) , 1941-1954
Abstract
Long-acting (LA) human immunodeficiency virus-1 (HIV-1) antiretroviral therapy characterized by a ≥1 month dosing interval offers significant advantages over daily oral therapy. However, the criteria for compounds that enter clinical development are high. Exceptional potency and low plasma clearance are required to meet dose size requirements; excellent chemical stability and/or crystalline form stability is required to meet formulation requirements, and new antivirals in HIV-1 therapy need to be largely free of side effects and drug-drug interactions. In view of these challenges, the discovery that capsid inhibitors comprising a quinazolinone core tolerate a wide range of structural modifications while maintaining picomolar potency against HIV-1 infection in vitro, are assembled efficiently in a multi-component reaction, and can be isolated in a stereochemically pure form is reported herein. The detailed characterization of a prototypical compound, GSK878, is presented, including an X-ray co-crystal structure and subcutaneous and intramuscular pharmacokinetic data in rats and dogs.Keywords
This publication has 34 references indexed in Scilit:
- In VitroCross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance MutationsAntimicrobial Agents and Chemotherapy, 2013
- Long-acting injectable antiretrovirals for HIV treatment and preventionCurrent Opinion in HIV and AIDS, 2013
- Large-Scale Functional Purification of Recombinant HIV-1 CapsidPLOS ONE, 2013
- Data processing and analysis with theautoPROCtoolboxActa Crystallographica Section D Structural Biology, 2011
- HIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionPLOS Pathogens, 2010
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- electronic Ligand Builder and Optimization Workbench(eLBOW): a tool for ligand coordinate and restraint generationActa Crystallographica Section D Structural Biology, 2009
- X-Ray Structures of the Hexameric Building Block of the HIV CapsidCell, 2009
- Atropisomeric quinazolin-4-one derivatives are potent noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonistsBioorganic & Medicinal Chemistry Letters, 2001
- Benzomalvin D, a New 1,4-Benzodiazepine AtropisomerJournal of Natural Products, 1995